Arcus Biosciences, Inc. RCUS 深 滬
已收盤 02-06 16:00:00 美东时间
21.03
+1.000
+4.99%
華盛通- 最 高21.095
- 今 開20.60
- 成交量 83.31万股
- 最 低 20.14
- 昨 收 20.03
- 總市值 25.59亿
- 52周最高 26.40
- 市盈率 靜 --
- 換手率 0.68%
- 52周最低 6.50
- 委 比 1.01%
- 總股本 1.22亿
- 歷史最高 49.10
- 量 比 0.90
- 振 幅 4.77%
- 歷史最低 6.30
- 每 手 1
- 風險率 5.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Morgan Stanley Downgrades Arcus Biosciences to Equal-Weight, Lowers Price Target to $20
Morgan Stanley analyst Terence Flynn downgrades Arcus Biosciences (NYSE:RCUS) from Overweight to Equal-Weight and lowers the price target from $23 to $20.
01-08 20:11
TIGIT的转机还会出现吗？
文 | 氨基观察 被寄予“下一个免疫检查点”厚望的TIGIT，几乎走到了临床验证的尽头。 12月12日，Arcus Biosciences宣布其与吉利德合作研...
2025-12-19 10:36
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
2025-12-13 02:35
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for casdatifan, a
2025-12-12 21:33
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
2025-12-01 14:33
B of A Securities Maintains Neutral on Arcus Biosciences, Raises Price Target to $26
B of A Securities analyst Jason Zemansky maintains Arcus Biosciences (NYSE:RCUS) with a Neutral and raises the price target from $17 to $26.
2025-11-29 01:03
Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Keysight Technologies Inc (NYSE:KEYS) rose sharply in pre-market trad...
2025-11-25 18:50
